WITTEN, Germany--(BUSINESS WIRE)--Sangui Biotech International, Inc. has filed a preliminary S-1 Registration Statement with the Securities and Exchange Commission. It is being expected that the SEC will declare the Prospectus effective within the next couple of weeks. The exact timeline depends on SEC approval procedures which cannot be anticipated by the company. The S-1 becoming effective is prerequisite for Sangui to start drawing upon the financial framework agreement with US investor Sout
| < Prev | Next > |
|---|
